News
BOLT
1.100
0.00%
0.000
Weekly Report: what happened at BOLT last week (0422-0426)?
Weekly Report · 5d ago
Weekly Report: what happened at BOLT last week (0415-0419)?
Weekly Report · 04/22 09:07
Weekly Report: what happened at BOLT last week (0408-0412)?
Weekly Report · 04/15 09:06
Weekly Report: what happened at BOLT last week (0401-0405)?
Weekly Report · 04/08 09:07
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aesthetic Medical Intl (NASDAQ:AIH) shares rose 14.0% to $0.52 during Wednesday's after-market session. Kineta shares rose 8.46% and Simulations Plus shares increased by 6.74%. The company's market cap stands at $24.9 million.
Benzinga · 04/03 20:31
Weekly Report: what happened at BOLT last week (0325-0329)?
Weekly Report · 04/01 09:07
Bolt Biotherapeutics: A Strong Buy on Clinical Progress and Financial Stability
TipRanks · 03/25 15:05
Weekly Report: what happened at BOLT last week (0318-0322)?
Weekly Report · 03/25 09:07
Bolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendation
Leerink Partners analyst Daina Graybosch has maintained their bullish stance on Bolt Biotherapeutics stock. The analyst sees potential in the upcoming clinical data expected in 2024. The company is developing a first-in-class immuno-oncology therapy.
TipRanks · 03/25 01:27
Bolt Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/22 15:10
Bolt Biotherapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 15:10
HC Wainwright & Co. Maintains Buy on Bolt Biotherapeutics, Maintains $8 Price Target
Benzinga · 03/22 15:00
Analysts Offer Insights on Healthcare Companies: BioNTech SE (BNTX), Intuitive Surgical (ISRG) and Bolt Biotherapeutics (BOLT)
TipRanks · 03/22 10:21
BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023
Bolt Biotherapeutics reported results for the fourth quarter of 2023. The company reported revenue of $2.09 million. Bolt BiotherAPEutics reported earnings per share of -47 cents. This was above the analyst estimate for EPS of -48 cents.
Investorplace · 03/22 02:53
Bolt Biotherapeutics GAAP EPS of -$0.47 in-line, revenue of $2.1M beats by $0.31M
Earnings News Bolt Biotherapeutics GAAP EPS of -$0.47 in-line, revenue of $2.1M beats by $0.31M. Cash balance of $128.6 million anticipated to fund key milestones through late 2025. Q4 GAAP earnings of $1.47 per share.
Seeking Alpha · 03/21 20:54
*Bolt Biotherapeutics: Cash Balance of $128.6 M as of Dec 31 Anticipated to Fund Key Milestones Through Late 2025 >BOLT
Dow Jones · 03/21 20:10
*Bolt Biotherapeutics 4Q Rev $2.09M >BOLT
Dow Jones · 03/21 20:07
*Bolt Biotherapeutics 4Q Loss/Shr 47c >BOLT
Dow Jones · 03/21 20:05
Press Release: Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update. BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones. Cash balance of $128.6 million anticipated to fund key milestones through late 2025.
Dow Jones · 03/21 20:05
Press Release: Bolt Biotherapeutics Reports -2-
Bolt BiotherAPEUTICS, Inc. And its subsidiaries have reported financial results for the three months and years ended December 31, 2018 and 2017. The company's net loss for the period was $16.7 million. The company expects to have a net loss of $15.1 million for the year ending December 30, 2018.
Dow Jones · 03/21 20:05
More
Webull provides a variety of real-time BOLT stock news. You can receive the latest news about Bolt Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BOLT
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The Company's pipeline candidates are built on its expertise in myeloid biology and cancer drug development. Its pipeline includes trastuzumab imbotolimod (formerly BDC-1001), a human epidermal growth factor receptor 2 - targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. Trastuzumab imbotolimod is in Phase 2 clinical. BDC-3042, an agonist antibody targeting Dectin-2, is in a Phase 1 dose-escalation trial. In preclinical development, BDC-3042 demonstrated the ability to convert tumor-supportive macrophages to tumor-destructive macrophages. It developed a lead agonist antibody that binds to Dectin-2 and activates human tumor-associated macrophages. It is developing multiple Boltbody ISACs in strategic collaborations with biopharmaceutical companies.